knowledge -WSS

knowledge

author：explore 2025-08-12 09:09:10 - browse：6979

ESMO signage in Madrid. — At ESMO 2023, antibody-drug conjugates were featured prominently. Andrew Joseph/STAT

MADRID — If you had to pinpoint one subject that stood out at this year’s European Society for Medical Oncology meeting, a massive conference with thousands of people from 140-some countries and 2,500 studies presented, it would be a burgeoning type of cancer treatment called antibody-drug conjugates.

The conference opened to the news that Merck had signed one of the biggest licensing deals in industry history — worth up to $22 billion — to partner on three of the compounds from ADC specialist Daiichi Sankyo. GSK followed up with an ADC licensing announcement of its own (if a much smaller one). Multiple ADC studies were presented at the meeting’s top sessions. ADCs were, in short, the belle of the cancer research ball.

The thing is, ADCs are actually quite an old approach.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Doctors increasingly discourage vaping amid mounting health concerns

WSS

The Bio Revolution is changing business and society

The world needs the new pandemic treaty

Putin woos African leaders at a summit in Russia with promises of expanding trade and other ties

The HPV vaccine prevents cancer in men, too. Why do so few people get it?

The world needs the new pandemic treaty

Unmasking the 'centricity' illusion in clinical trials

entertainment

knowledge

knowledge

The high cost of giving birth even with insurance

Why we need mandatory labeling of GMO products

Continuity nursing helped my family in our darkest PICU moments

Louisiana bill approved classifying abortion pills as controlled substances

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Judge orders hearing on Trump's motion to disqualify Fulton County DA

How to save PrEP access — and even expand it

What AstraZeneca

Cancer drug shortages should be causing more outrage

Asahi Kasei to buy Calliditas, picking up kidney disease drug

hotspot

U.S. death rates show how politics are affecting public health

Clinicians often fail to acknowledge the pain caused by long Covid

Hospitals need to get ahead of regulations on climate change

New research sheds light on how often breast cancer is overdiagnosed

Young Chinese opt out of the rat race and pressures at home to pursue global nomad lifestyle

Duchenne drug from Nippon Shinyaku fails in rare confirmatory trial

focus

hotspot

explore

leisure time